Checkpoint therapies, once primarily used to treat metastatic cancer patients, are now being applied to earlier stages of cancer. Researchers are grappling with the optimal approach to utilizing these treatments for less-advanced cancers. This shift in treatment landscape has sparked debate among medical professionals about how best to utilize checkpoint inhibitors, potentially transforming patient outcomes.
Source: https://endpts.com/asco25-researchers-debate-how-best-to-use-checkpoint-drugs-in-earlier-cancers